Innovent Expands Phase 3 MarsLight-11 Trial of IBI363/TAK-928 to Non-Squamous NSCLC
Innovent and Takeda expand the Phase 3 MarsLight-11 Trial to include non-squamous NSCLC patients, doubling the addressable population for...
Akeso Enrolls First Patient in Phase III Trial of Cadonilimab vs Nivolumab for Gastric Cancer
Akeso launches COMPASSION-37, a global Phase III trial of cadonilimab versus nivolumab for HER2-negative gastric cancer, testing dual checkpoint...
Headlands Research Joins SCRS Global Impact Partner Program
Headlands Research joins SCRS Global Impact Partner program to address site sustainability and trial complexity challenges in clinical operations.
Kodiak Sciences to Report DAYBREAK Phase 3 Results for Zenkuda and KSI-501
Kodiak Sciences reports DAYBREAK Phase 3 results for Zenkuda and KSI-501 in wet AMD on September 28, testing non-inferiority...
Five Barriers Block Rare Disease Patient Enrollment in Clinical Trials
Five compounding barriers—awareness, protocol complexity, competition, hesitancy, and logistics—block rare disease patient enrollment in clinical trials.
Annamycin Shows Immune Activation in Pancreatic Cancer Preclinical Study
Annamycin shows immune activation in pancreatic cancer preclinical study, with CD8+ T cells mediating antitumor activity alongside cytotoxic effects.
ELI-002 7P Phase 2 Data Selected for ESMO 2026 Oral Presentation
ELI-002 7P Phase 2 data selected for oral presentation at ESMO 2026, showing signals in patients with lower residual...
CARVYKTI achieves five-year treatment-free remission in 50% of early-line myeloma patients
CARVYKTI achieves five-year treatment-free remission in 50% of early-line myeloma patients, with no additional therapy required after single infusion.
FDA approves baricitinib for severe alopecia areata in adolescents 12+
FDA approves baricitinib for severe alopecia areata in adolescents 12+, with 42% achieving 80% scalp hair coverage in Phase...
Phase III Trial Amendments Average 3.5, Up From 2.3 a Decade Ago
Phase III trial amendments now average 3.5 per study, up from 2.3 a decade ago, with each costing a...